格隆汇11月18日丨朝聚眼科(02219.HK)发布公告，2025年11月17日，董事会已决议根据股份购回授权， 自2025年11月17日起不时于公开市场购回最多价值5000万港元的公司股份。 ...

Core Insights - The event organized by Shenzhen Stock Exchange aimed to deepen investors' understanding of Aier Eye Hospital's (300015) listed company status and its role in the ophthalmology sector [1] Group 1: Company Overview - Aier Eye Hospital maintains international synchronization and domestic leadership in refractive technology, offering a wide range of surgical procedures that are continuously upgraded [2] - The company emphasizes personalized medical services based on the principle that "the suitable is the best," leading to increased patient recognition of advanced techniques like "All Light Plastic," "All-Femto 4.0," and "All-Femto Pro" [2] Group 2: Business Development - Aier's business structure optimization has resulted in a steady increase in average pricing, demonstrating effective measures against market saturation [2] - The company's vision care business has developed a comprehensive system from prevention to treatment, enhancing its core competitiveness through an integrated medical education and research platform [2] Group 3: Market Expansion - Investors are particularly interested in Aier's international expansion, with the company acknowledging the vast potential of the overseas ophthalmology market [2] - Aier plans to pursue internationalization more actively and cautiously, focusing on healthy growth of existing overseas institutions while enhancing its medical network in surrounding regions [2]

Core Viewpoint - The company, Aier Eye Hospital Group, emphasizes its commitment to maintaining technological advancement in response to investor inquiries [1] Summary by Relevant Categories Company Developments - Aier Eye Hospital Group is closely monitoring new developments in the industry [1] - The company is dedicated to sustaining its technological leadership [1]

Core Viewpoint - The company, 德视佳 (01846.HK), reported an increase in the total number of ophthalmic surgeries performed in Q3 2025, reaching 6,807 cases, which is approximately 5.6% higher than the same period in 2024 [1] Summary by Category Company Performance - The total number of ophthalmic surgeries in Q3 2025 was 6,807, up from 6,445 in Q3 2024 [1] - The growth in surgeries is attributed to an increase in the number of lens replacement surgeries and a recovery in laser surgery volumes [1] Market Demand - The positive change in surgery numbers reflects a growing patient demand, contributing to the overall performance improvement of the company [1]

德视佳(01846)发布公告，于2025年第三季度，本集团进行的眼科手术总数为6807例，较2024年同期增 加约5.6%(于2024年9月30日：6445例)。有关增长主要是由于晶体置换手术数量增加以及激光手术量恢 复。该积极变化反映于2025年第三季度的患者需求不断增长，有助于提升整体表现。 ...

Core Viewpoint - The company reported a total of 6,807 ophthalmic surgeries in Q3 2025, representing an increase of approximately 5.6% compared to the same period in 2024, driven by a rise in lens replacement surgeries and a recovery in laser procedures [1] Summary by Category Company Performance - The total number of ophthalmic surgeries performed by the company in Q3 2025 was 6,807, up from 6,445 in Q3 2024 [1] - The growth in surgeries is attributed to an increase in lens replacement surgeries and a recovery in laser surgery volumes [1] Market Demand - The positive change in surgery numbers reflects a growing patient demand, contributing to the overall performance of the company [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而產生或因倚賴 該等內容而引致之任何損失承擔任何責任。 EuroEyes International Eye Clinic Limited 德視佳國際眼科有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1846） 自願公告 2025年第三季度的眼科手術總數 德視佳國際眼科有限公司（「本公司」，連同其附屬公司，統稱「本集團」）自願刊發 本公告。本公司董事（「董事」）會（「董事會」）謹此宣佈，根據本公司的初步統計 數據及本公司目前可得的資料，統計本集團於2025年7月1日至2025年9月30日期 間（「2025年第三季度」）進行的眼科手術（統稱「眼科手術」）總數。 於2025年第三季度，本集團進行的眼科手術總數為6,807例，較2024年同期增加 約5.6%（於2024年9月30日：6,445例）。有關增長主要是由於晶體置換手術數量 增加以及激光手術量恢復。該積極變化反映於2025年第三季度的患者需求不斷增 長，有助於提升整體表現。 本公告所載數字未經審核 ...

Group 1 - A block trade of 689,300 shares of Aier Eye Hospital was executed on November 13, with a transaction value of 8.7886 million yuan and a transaction price of 12.75 yuan, representing a premium of 3.57% over the closing price of the day [2][3] - In the last three months, Aier Eye Hospital has recorded a total of 7 block trades, with a cumulative transaction value of 70.7487 million yuan [2] - The closing price of Aier Eye Hospital on the day of the block trade was 12.31 yuan, reflecting a 0.24% increase, with a daily turnover rate of 0.61% and a total trading volume of 593 million yuan [2] Group 2 - The latest margin financing balance for Aier Eye Hospital is 2.544 billion yuan, with an increase of 8.6439 million yuan over the past five days, representing a growth rate of 0.34% [3] - Aier Eye Hospital Group was established on January 24, 2003, with a registered capital of 932,539.667 million yuan [3]

Core Insights - The 19th World Association of Eye Hospitals (WAEH) annual meeting was successfully held in Lausanne, Switzerland, and Paris, France, focusing on clinical innovations powered by artificial intelligence, talent cultivation in ophthalmology, and patient-centered high-quality eye care development models [1][6] - Aier Eye Hospital Group, as the only board member from China, was re-elected to the WAEH board, representing Chinese ophthalmology on the international stage [1][6] Group 1 - Aier Eye Hospital's experts presented innovative clinical practices and management models at the conference, showcasing the establishment of nearly 200 intravitreal injection centers and a digital follow-up system that enhances patient care [3] - The dry eye clinic's capabilities and standardized management were discussed, emphasizing the importance of specialized services in improving treatment efficiency and patient satisfaction [3] - Aier Eye Hospital received recognition for eight posters presented at the conference, with one project winning the "Best Poster Award" for its innovative training system in refractive surgery [4] Group 2 - The conference highlighted the increasing global influence of Chinese ophthalmology, with more institutions participating in international dialogues and sharing innovative practices, such as Shanghai's model for public health eye management [6] - Aier Eye Hospital has been actively promoting the sharing of Chinese ophthalmic experiences internationally since becoming a board member in 2021, and it successfully hosted the 18th WAEH annual meeting in Changsha, China [6] - The next WAEH annual meeting will be held in South America, with interest from various countries, including China, in hosting future events, reflecting the academic and industry value of the conference [7]

Investment Rating - The investment rating for the company is "Buy" and is maintained [8]. Core Insights - The company's performance meets expectations with steady revenue growth. For the first three quarters of 2025, the operating revenue reached 3.272 billion yuan, a year-on-year increase of 2.83%. In the third quarter alone, the operating revenue was 1.133 billion yuan, growing by 0.13% year-on-year. The overall gross margin remains stable, with a gross margin of 44.71% in Q3 2025, slightly down from 45.44% in Q2 2025. Future growth in gross margin is anticipated as the company continues to focus on high-quality services, awaiting a return to higher revenue growth rates [5][11]. Summary by Sections Financial Performance - For the first three quarters of 2025, the company reported an operating revenue of 3.272 billion yuan, up 2.83% year-on-year, and a net profit attributable to shareholders of 434 million yuan, an increase of 3.04%. In Q3 2025, the operating revenue was 1.133 billion yuan, with a net profit of 152 million yuan, down 2.37% year-on-year [5][11]. Strategic Initiatives - The company adheres to a dual-driven strategy of "internal growth + external mergers and acquisitions." It leverages the Xiamen Eye Center as a core, utilizing its leading diagnostic and treatment capabilities along with mature hospital management experience. The company has established a standardized high-quality medical service and management system across its chain of hospitals, expanding its ophthalmology network to 64 specialized hospitals and 67 optical centers across 19 provinces and municipalities by mid-2025 [11]. Research and Development - The company emphasizes the "coordinated development of medicine, education, and research," focusing on eye disease treatment. It has established a comprehensive medical education and research system, collaborating with over 40 universities, including Peking University and Xiamen University. This collaboration covers talent training, academic co-construction, and clinical research, with over 380 national and provincial research projects initiated and 1,641 academic papers published by mid-2025 [11]. Profit Forecast and Investment Advice - The company is projected to achieve net profits attributable to shareholders of 540 million yuan, 640 million yuan, and 730 million yuan for 2025, 2026, and 2027, respectively. The current stock price corresponds to price-to-earnings ratios of 30, 25, and 22 times for the respective years, maintaining a "Buy" rating [11].